TCON - Tracon Pharma announces positive results from phase 2 trial of Envafolimab
- Tracon Pharma ( NASDAQ: TCON ) is trading ~17% higher premarket after the company announced positive data from a phase 2 trial testing its drug, Envafolimab, as monotherapy and in combination with Yervoy, to treat solid tumors.
- The Independent Data Monitoring Committee reviewed interim safety and efficacy data from 18 patients enrolled into each cohort who completed a minimum of 12 weeks of efficacy evaluations in the mid-stage trial.
- The company said the double-digit Objective Response Rate assessed by blinded independent central review in each cohort more than satisfied the prespecified futility rule.
- Responses were noted in patients regardless of weight at the 600 mg dose of envafolimab.
- “Achieving a double-digit ORR with a well tolerated safety profile, as both monotherapy and in combination, positions envafolimab to become a potential treatment option for patients with refractory UPS and MFS,” said Charles Theuer, TRACON’s Chief Executive Officer.
For further details see:
Tracon Pharma announces positive results from phase 2 trial of Envafolimab